GlassScriptPhysician profile
Yana Garger
NPI 1366604704
$2,981.48
in general payments reported to CMS, 2019-2025
20 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.96 · 2020: $28.12 · 2021: $197 · 2022: $540 · 2023: $414 · 2024: $427 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.87 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $680.09 | 2021-2025 | Evenity, Prolia |
| Amneal Pharmaceuticals LLC | $533.31 | 2021-2025 | Unithroid |
| Chiesi USA, INC. | $300.00 | 2025 | Mycapssa |
| Novo Nordisk INC | $285.82 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $268.82 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $261.61 | 2021-2025 | Freestyle Libre 3 |
| Insulet Corporation | $162.62 | 2022-2025 | Omnipod |
| Radius Health, INC. | $119.34 | 2022-2025 | Tymlos |
| Abbvie INC. | $113.99 | 2020-2024 | |
| Astellas Pharma US INC | $40.99 | 2025 | Veozah |
| Medtronic, INC. | $39.79 | 2022-2023 | Minimed 780g |
| Ibsa Pharma INC. | $37.30 | 2024 | Licart, Tirosint |
| Tandem Diabetes Care, INC. | $32.80 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alvogen INC | $17.42 | 2025 | Teriparatide |
| Dexcom, INC. | $15.86 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.59 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $14.96 | 2019 | |
| Merck Sharp & Dohme LLC | $14.55 | 2021 | |
| Ascendis Pharma Endocrinology INC | $14.00 | 2025 | Yorvipath |
| Amryt Pharma Holdings LTD | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yana Garger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.